drugset
drugset / Trial / NCT04369430

Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

NCT04369430 ↗

Phase 2 Completed 110 enrolled Alkahest, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.

Timeline

Start
2020-01-16
Primary completion
2021-02-11
Completion
2021-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject LAZUCIRNON Small molecule 400 mg Oral

Indications

Parkinson disease